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Ethical Issues in

AIDS Research

Michael A. Grodin, M.D.
Paula

V.

Kaminow,

J.D.

Raphael Sassower, Ph.D.

a need for carefully controlled and scientifically rigorous research studies of the
acquired immunodeficiency syndrome (AIDS). The morbidity and mortality associated
There

with

is

AIDS patients and the public health concerns for control of this epidemic have dis-

torted the usual process of research.
tal is

The Institutional Review Board at Boston City Hospi-

suggested as an appropriate mechanism for clarifying the distinctions between

and innovative therapies and for assuring the protection of this vulnerable popuof research subjects. This article addresses ethical concerns relating to the time
frame of research, drug and antibody testing, vaccine trials, and questions ofjustice in
research
lation

micro- or macro-allocation. The unique problems in

AIDS research

with informed consent

and confidentiality are discussed. Finally, the need is outlined for careful balancing of
individual welfare and rights and those of society.

Perhaps the least controversial point in all discussions about AIDS and AIDS-related
complex (ARC)
history, epidemiology,

is

The need to discover the

the need for research.

and treatment of AIDS

is

etiology, natural

indisputable. However, ethical

dilemmas

surrounding the priorities, methodologies, and timing of research strategies pose unique

problems for

patients, researchers, clinicians, hospitals, institutional review boards

(IRBs), public health workers, health care policymakers, and society at large.

From the

earliest case reports in late

1

1979 of male homosexuals with Kaposi's sarcoma,

immunosuppression, and opportunistic infections, through

May

1984,

when

the

human

immunodeficiency virus (HIV, formerly known as HTLV-EQ/LAV) was accepted as the
etiologic agent of AIDS, to the present, medical scientists have

been and continue

to

be

involved in clinical, epidemiological, and basic science research into AIDS. 2 The Centers
for Disease Control

(CDC) has been

involved in surveillance and epidemiological re-
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search, while other federal agencies, such as the National Institutes of Health and the

National Cancer Institute, have sponsored and carried out other investigations. Privately

funded commercial, pharmaceutical, and hospital-based research has also been

The rapid mobilization of the medical research community

initiated.

in the face of this deadly,

im-

mensely complex, and emotionally charged public health problem has caused some wobbles in the balance that

public welfare

is

carefully maintained between individual patient welfare and the

— a balance that has always been an integral part of the ethical principles of

medical research.

The Nature of AIDS Research
The primary goal of medical research

is

to contribute to the

development of general

knowledge about a particular disease or condition; the primary goal of clinical therapy, on
the other hand,

is

to benefit the individual patient.

When medical research enters the

form of testing new drugs, vaccines, or diagnostic procedures, a blurring between these two objectives often occurs. The goal of participating in
clinical therapy setting in the

the testing of a

new drug or an innovative therapy may be one thing

clinician team, another for the research scientist,

and quite another

for the patient

and the

for the sponsoring

agency.

The potentially competing

interests of the various parties involved in

tation present a crucial issue in

AIDS

research. Additional surveillance

human experimenis

of the wide array of unvalidated and innovative therapies being tested on

needed because

AIDS patients —

who may be willing to incur greater
good of others. This surveillance must be undertaken by a group
represents the interests not only of the researchers and sponsoring agencies but also

members of a

special population with a fatal disease

risk to themselves for the
that

of the patients and the public at large.

Boards
IRBs are the intra-institutional committees established under regulations promulgated by
the U.S. Department of Health and Human Services. 3 They are mandated to review research involving humans and to monitor the protection of human subjects in order to ensure that socially accepted ethical norms are met. 4 IRBs require that research protocols
involve sound scientific design; competent methods of investigation; favorable balance of
risks and benefits; adequate informed-consent mechanisms; equitable selection of sub-

Institutional Review

on special populations; and consideration of compensation
Those who comprise IRBs fall into one of two groups,

jects; justification for research

for research-induced injury.

broadly speaking: individuals

who are affiliated with the institution or hospital, such as

physicians, nurses, scientists, pharmacists, and public health workers; and unaffiliated
lay

members, such as philosophers, theologians, lawyers, and other community repreSuch broad representation and mandated authority place IRBs in the pivotal

sentatives.

position necessary to provide additional surveillance of AIDS research.

Time Frame for Research
The high morbidity and mortality of AIDS

patients

and the serious public health concerns

regarding the etiology, natural history, and transmission of HIV have accelerated the
standard medical research time frame for

up AIDS research

is

AIDS research. Although the pressure to

speed

understandable, perhaps even desirable, such distortion of standard

research practice implies potential dangers. Moreover, the publicity concerning
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AIDS

re-

search has created a public image of medical research that

Standard medical research

is

is

a slow, meticulous process.

quite different

Once the

safety

from

reality.

and efficacy

of proposed therapies have been established, controlled clinical tests are performed. To

minimize human

human studies; comwhen applicable,

animal studies are used when possible before

risk,

petent adult patients are studied before incompetent patients; and,

healthy volunteers are studied before sick or exposed volunteers. Special protections are

needed

As

for the study of populations

who are at

special risk of possible coercion or duress.

a rule, indiscriminate or premature use of therapies that have not been vigorously

tested

In

and verified

AIDS

is

discouraged.

research, however, there has been a rapid

ies to clinical trials.

movement from basic-science

stud-

Researchers have been quick to report the results of their work, and

news media. Data
where they are often

the publication of these results has been almost immediate through the

from such research may be quickly transferred
applied without controlled clinical testing. This
able to treat their

to the clinical setting,
is

understandable. Physicians want to be

AIDS patients as effectively as possible, and they

also want to be able to

educate their patients and the public appropriately in order to prevent the spread of AIDS.

AIDS patients,

searching for hope of survival, scan the medical literature and news re-

ports for access to

new drugs

or therapies. Premature media coverage of research results

has often been accompanied by unwarranted claims of success, thereby raising the public's

When the initial studies of interferon and interleukins were
AIDS patients from all over the country flooded researchers with

expectations unfairly.

released by the press,

requests for treatment.

Public health concerns about the prevention and spread of AIDS have caused the early
introduction of research data into public policy debates. Epidemiological studies are

sought as a means of dealing with disease risk management. Such data are used in argu-

ments

for

and against policies regarding persons with

AIDS and their school

attendance;

the safety and appropriateness of their employment; acceptance for health and life insur-

ance; and possible large-scale screening and quarantine.

Through the rapid publication of their data, many

investigators have gained professional

and personal renown as well as guarantees of future research funding. The race

to cure

AIDS has even spurred one research team in France to bring a legal suit against a U.S.based research team in an argument over who really discovered the AIDS virus.
The rather unorthodox methodology of AIDS research has led to several problems.
5

Data are presented which have not been adequately tested or controlled. Reports of conflicts in

data or errors in data cause alarm

among

clinicians

and patients

alike.

Premature

claims of certainty about results which prove to be inaccurate and the continual updating

and reclarifying of results of epidemiological studies and
public and shaken

its

confidence in

clinical tests

have confused the

AIDS research.

Because of the urgency of AIDS research, IRBs have
researchers and the public to approve

felt

increased pressure from both

AIDS research protocols rapidly.

function and responsibility of IRBs to protect

human

Since

it is

both the

subjects in medical research, they

must assume the crucial tasks of helping to maintain ethical and standard research procedures and of helping to develop responsible modifications in those procedures. However,
IRBs cannot and should not be the sole gatekeepers safeguarding the integrity of AIDS
research.

AIDS Drug Testing
The discovery of experimental

antibiotics

and

antiviral agents that
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may

help fight

AIDS
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and the complicating opportunistic infections found

in

AIDS patients has

spurred the

early clinical testing of such drugs. Research protocols involving these drugs represent

some of the most ethically complex situations that come before IRBs. Researchers ask
IRBs for approval to bypass standard research procedures and to grant compassionate use
of drugs they believe will be of particular benefit to
cal

companies are eager

new

to introduce their

AIDS patients.

antiviral products,

mere suggestion of the possible success of an experimental

Private pharmaceuti-

because sometimes the
caused

antiviral agent has

stock in the companies producing such drugs to rise rapidly. Requests are also
special, expedited approval for

new

uses of approved drugs without controlled

made

for

trials

or

standardized testing.

An excellent example of the dilemmas associated with drug testing in AIDS patients is
6
the case of Azidothymidine (AZT).

have some efficacy with the
series of questions arose.
ical

AIDS

From the moment this antiviral agent was shown to

virus,

an emotionally charged and ethically complex

Should the drug go through the standard three-phase, slow med-

research protocol of exhaustive testing of safety and efficacy in animals and humans?

What patients should be used in human

experimentation, and

how should they be

lected? Should a standard controlled clinical trial of the experimental agent

se-

matched

against a placebo-control group be undertaken to prove clinical efficacy scientifically?

How much of a role should AIDS patients, ARC patients, physicians, scientists, drug
trials of AZT? If a ran-

companies, and the public play in determining the research

domized clinical

trial

of placebo versus

AZT were undertaken, at what point should the
AZT and which received placebo in

code be broken, identifying which patients received

such a blind study? Once a trend toward efficacy has been established in the course of
clinical experimentation,

ble? Is a desperately
patients with

ill,

when should the trials be terminated and the drug made availa-

dying patient with

AIDS the appropriate subject for study,

or are

ARC or HIY-antibody -positive patients with no symptoms a more justifiable

group in which

to

conduct clinical

trials?

How

should one assess the relative risks and

benefits in these populations? Should dying patients be included in the randomization, or

should they be treated with drugs outside of clinical
patients

who are dying

give an informed consent?

trials as

Even

a last glimmer of hope?

if they

Can

are competent to do so,

should they be approached with new, untested drugs with no clear evidence of safety or
efficacy?

Who should bear the cost of the research project and of the drugs themselves? If

a drug appears to be effective late in a clinical

pay for the drug? After the research

trials

trial,

can the research subject be asked to

are over, can a patient

who appears

to

have

responded continue to have access to the experimental agent? As newer drugs become
available, should they

be tested against placebo controls or against other existing drugs,

AZT? What control

should IRBs have in the resolution of these dilemmas? And,
what role should such regulatory bodies as the Department of Health and Human
Services or the Food and Drug Administration (FDA) play in monitoring and granting

such as

finally,

final approval for

The

AIDS

history of AZT,

drugs?

from

its

human testing and then to FDA

early synthesis as an anticancer drug through animal and

approval and marketing, represents a fair balance between

the expediency of drug development and the protection of human subjects at risk.

AZT

was first tested for in vitro activity against HIV. When the drug's efficacy with HIV had
been demonstrated, animal trials were undertaken. The first human experiments were
conducted at the National Cancer Institute as an open, nonrandomized trial. Once AZT
showed promise as an agent in vivo against HIV, a randomized, placebo-controlled clinical trial was carried out at several medical institutions caring for AIDS patients. Early in
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the controlled trials, researchers broke the code to identify patients receiving the drug

when

it

became apparent that some patients benefited from the

On the basis of accumulated data from these trials,
March

use on
its

the

trial

more than

AZT was approved, the manufacturer began to charge for
AZT was approximately $10,000 per year, but the increasing

19, 1987. After

use. Initially the cost of

market and efficiency of production have already led the manufacturer
this figure.

others.

FDA approved AZT for clinical

However, the cost may

still

to

begin lowering

present an economic hardship for some. Increased

production of the drug seems to have alleviated the problems of access that accompanied
its

emergence. Insurance coverage

may vary, though

it

appears that access has not been

limited nationally by inability to pay. In Massachusetts,

all

third-party payers, including

Medicaid, have covered the cost of AZT. Massachusetts has also recently established a

program to cover

the cost of the drug for patients

who have no other means to pay. AZT

has thus proven to be a paradigm for a reasonable approach to drug testing in AIDS.
In June 1987, partly in response to
outlining procedures under
available to desperately

ill

AIDS drug testing,

the

FDA issued final regulations

which "promising, investigational new drugs could be made

patients before general marketing begins."

7

The regulation

applies to "patients with serious and immediately life-threatening diagnoses for

comparable or satisfactory alternative drug or other therapies
fined "conditions under which drug manufacturers

drug products."

It

remains to be seen whether such

plish the goal of releasing

new drugs

exist."

may charge

The FDA

which no

also de-

for investigational

new

FDA regulatory changes will accommarketing while

to patients prior to

at the

same time

protecting the scientific clinical-trials process for testing safety and efficacy and protect-

ing the

human

HIV Antibody

subjects participating in research.

Testing

Perhaps the clearest example of the quick transition of AIDS research from the laboratory

HIV antibody test. Because of the need to identify subjects carrying the
HIV antibody in order to protect the blood supply from contaminated donor units, antibody testing was one of the first priorities of AIDS research. The test was also necessary
to the clinic is the

for quantifying epidemiological data

oped, the

and for therapeutic

trials

and screens. Once devel-

HIV antibody test was rapidly introduced into research protocols and clinical

practice, but

problems of sensitivity and specificity resulted because experience with the

significance and variances of the test was not complete.
tions about the reliability of HIV antibody positivity

false-negative rates caused concern about

how

Beyond

is

ques-

quickly this test was being used for clinical

screening and public policy guidelines. Extending the use of the
patient care

test reproducibility,

and the significant false-positive and

HIV antibody test to
why it should be

complicated by the questions of where, when, how, and

used. In using antibody testing, the distinctions between purposes of epidemiology, diagnosis,

and public policy have not always been

clear.

HIV Vaccine
As more is learned about the structure and function of the AIDS virus, several research
groups have begun work on the development of an HIV vaccine. If and when such a vaccine becomes available, how should it be tested? Do safety and efficacy studies in animals
warrant the move to human studies? Who should be used for human studies — patients
who are already infected with the virus, or normal subjects with no evidence of viral
infection? Is it appropriate to test the vaccine on at-risk populations when education and
change in lifestyle are known to be effective preventive measures? Once the vaccine is

219

New England Journal of Public Policy

administered,

how

will

immunity be tested? Should such subjects be challenged with the

virus or allowed or even encouraged to continue their high-risk behavior?

nization, but there will

recommendations

The laboratory

HIV vaccine may raise the hope of universal protection through immu-

development of an

for

be significant ethical debate about research

widespread

trials

and subsequent

clinical use.

Justice in Micro- Allocation

The main concern of persons with AIDS

is

the possible avoidance of what appears to be an

inevitable early death. This fact brings into focus the

AIDS

research.

be effective

in

participates in

It is

problem of population selection

combating AIDS. Are chances of survival increased when an

many

AIDS patient

How are
Who serves as the control group for these drug trials? Should

research protocols involving different experimental drugs?

participants to be selected?
selection be based

for

reasonable to assume that some experimental drugs will eventually

on the

ability to pay,

on special needs, or on

special merit? Since par-

AIDS research may be viewed as a public good that may also be helpful to the
individual AIDS patient, questions about distributive justice must be addressed. How
ticipation in

should promising experimental therapies be distributed

among

too

all

many

claimants in a

research setting?
Distributive justice also enters into the

AIDS

research.

problem of disseminating knowledge about

Who should know about it? How should such knowledge be provided?

Who should pay for it? Should the public as a whole bear the burden of learning and
teaching

all

there

is

to

know about AIDS? Should all

AIDS-related issues? Should

all

the

media

outlets devote time to

public schools devote regular sessions to AIDS-related

issues? Should the public be alerted as soon as possible to

all

new

stages of AIDS re-

search?

Justice in

Macro- Allocation

Most medical research

in the

United States

private foundations and corporations.

is

More

funded either by government agencies or by

specifically,

when the

national epidemics or to medical ailments that are of concern to a

research pertains to

wide portion of the

population, funding has been provided largely by government agencies. Because

was not viewed
initially

given

at first as

little

an epidemic of national concern, however,

attention

and

little

AIDS

AIDS

research was

funding.

Several explanations can be given for this early public policy decision. First,

AIDS was

thought to afflict only a small minority and thus was not a national concern. Second,

some viewed AIDS in theological terms and claimed that this disease was divine punishment against the immoral acts of homosexuals. Third, political pressure to do anything
about AIDS was lacking. This is understandable, given the politically conservative stance
of the current administration, especially toward the population at risk for developing

AIDS.
compromises regarding AIDS became quite evident to the growing population
AIDS patients. The male homosexual populations of cities like Boston, New
York, and San Francisco flexed their political muscles and demanded that their city govPolitical

of potential

ernments do something about AIDS. These powerful grassroots efforts provided the popular support that city

with

AIDS

mayors needed

to pressure their state legislators for funds to help

research and education programs. Finally, through pressure from local and
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state

governments and the public

funds for

AIDS

at large, the federal administration

began

research through the office of the secretary of health and

If only a marginal segment of the population

to provide

human

services.

afflicted with a certain disease,

is

reasonable and just that only a small proportion of public funds

earmarked

it

seems

for medical

research be allocated for the study of that disease. This was the original proposition advocated in the case of AIDS on both logical and ethical grounds. But this reasoning cannot
hold.

Now that cases of heterosexual partners and children with AIDS have been con-

firmed,
tial

it

how

remains unclear

small or large the at-risk population

risk to the public at large is uncertain,

it is

not obvious

is.

Because the poten-

how to proceed. Should funds

be provided only according to the proven proportion of the population which has already
contracted the disease?

Or should the potential spread of AIDS be taken into account?

Questions also arise concerning the priority of other ongoing medical research. Should
federal funding for the less urgent areas of medical research be halted and those funds

AIDS research? Such a suggestion could be defended if one were able to
show that unless the government did just that, millions of lives would be endangered.
Arguments of this sort presuppose that it is possible to establish a medical research
agenda with an agreed-upon set of priorities determined by society as a whole. There are,
of course, practical problems with setting such an agenda. How could all of society particchanneled to

Can any procedure guarantee democratic

ipate in such a discussion?

control of the setting

of these priorities?

A discussion of the macro-allocation of resources for AIDS research would not be complete without considering

what

it is

that private foundations

and corporations have

at stake

AIDS research. Are these organizations concerned with the well-being of those
afflicted with AIDS? Or are they hoping to discover the cure in order to capitalize on their
in funding

discovery and

make huge profits?

It is

possible to claim that the motives for research are

unimportant as long as the results are beneficial to patients and society. Moreover,

whether or not profits will be secured remains an open question that has

little

the ability of the private sector to supplement the federal funds allocated for
search. There are always potential conflicts of interest

research, in terms of compromises that might be

Although IRBs should be cognizant of these
is

limited to the ways in which financing

may

bearing on

AIDS re-

on the part of those involved

in

made to maximize profits.

issues, their

concern about funding sources

affect the well-being of human subjects. Is

there adequate funding to assure the completion of the proposed research, so that the

claimed benefits will indeed outweigh the risks the subjects are asked to incur?
also be noted that the role of the

agenda but merely

to

IRBs

is

It

should

not to set up or implement any specified research

ensure the protection of the subjects

who are enrolled in medical

research projects.
It is

impossible and would be presumptuous to provide any answers or even rules for

action regarding the

and

that

many

which follows

AIDS, both

is

questions raised so

to illustrate the

for society as a

whole and

far.

The main purpose of this discussion

complexity of the ethical issues surrounding

and
and political concerns.

for the individuals involved,

issues are intimately connected to other social

to

show

that these

Informed Consent
Obtaining informed consent in any type of research

is

a demonstration of respect for an

individual's autonomy. Informed consent has three primary components:
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• the individual giving consent is mentally competent;

• the individual giving consent is presented with

rational decisions;

• the consent is

enough information

to

make

and

uncoerced

— freely given by a nonvulnerable, autonomous

individual.

AIDS

when
new vaccine or treatment, both the scientific community and the subjects are faced with more unknowns than knowns. Because AIDS research is so new, the
range and magnitude of the unknowns are great. Researchers may believe that their ethical
research raises ethical questions about each of these components. First,

research involves a

obligations are fulfilled by advising the subjects of the range of unknowns and asking

them

to

ratio on that basis. However, at some point, parwhere new ideas are being rushed through the research system and virtually no

weigh the potential risk/benefit

ticularly

may be available, potential subjects may be placed at too great a risk. IRBs
make this kind of assessment and, if necessary, restrict participation in such a

information

need

to

study.

AIDS show clinical signs of a central nervous system dysAIDS virus. To the extent that such symptoms render them

Second, some persons with
function associated with the

mentally incompetent, they will be unable to give informed consent.

when

research

is

AIDS is, Who,

directed at central nervous system

A question that arises

if

anyone, can or

should give consent for the patient? This question arises in both clinical and research
settings. Generally, substitute decision

makers

(for

example, parent, spouse) are ap-

when an individual with AIDS is alienated from his or her
family and has no legally recognized spouse? The individual who is closest to and who
best knows the patient may not be legally recognized as such and may know of difficulties
proached. 8 But what happens

between the patient and other family members.
Third, and finally,

when research

involves a dying patient

by a continuous series of recurring infections and the patient

whose body has been ravaged
is given a glimmer of relief,

the consent can hardly be considered freely given by a nonvulnerable person. Or,

about the symptomatic or asymptomatic individual
possibility of having infected a loved

make amends? How about the

one and who

who

is

feels a sense of guilt

how

from the

willing to undergo unusual risks to

intravenous (IV) drug user

who may link the research with

access to methadone?

What obligations do
the individual?

researchers have to look beyond the surface of consent and protect

How paternalistic may the researcher be? Or,

a group uniquely infected by a virus under

some obligation

conversely, are

to society

members of

and the other

mem-

bers of their group to sacrifice their individuality in order to help avert further infection?

IRBs are in a position to protect the rights of individuals to make autonomous and informed decisions and not be pressured either by researchers or by the population of persons with AIDS. In this sense, then, IRBs may be considered paternalistic when attempting to maintain the rights and welfare of potential research subjects.

Confidentiality
Preservation of the confidentiality of individuals with

AIDS

research

is

AIDS or of other participants in

a major concern of clinicians, researchers, lawyers, ethicists, and com-
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munity groups. 9 The right

to privacy, as associated with individual liberty

is an important ideal in our society. All medical clinicians

and autonomy,

and researchers are obligated

to

maintain confidential information acquired in the clinical and research settings. In the
therapeutic environment, such ethical obligations are supported by legal rights in order to

permit a free exchange of information between patient and clinician so that possible benefits

of treatment will be maximized. The federal guidelines for federally funded research

require that researchers provide for confidentiality of records and subject information and

IRBs consider this issue when reviewing research protocols. 10
The complexity of AIDS research makes difficult demands on researchers with regard
to confidentiality. First, in a society in which homophobia exists and AIDS phobia runs
that

rampant, the risk of information leaks
erally for being gay or

There are cases

in

is

quite high. Individuals

drug users, or specifically for having a

which people

may be

stigmatized gen-

contagious disease.

fatal,

AIDS, ARC, or HIV antibody

either with

positivity have

been denied insurance benefits or have suffered the loss of their jobs. Medical providers,

on their unsubstantiated fears of treating individuals with AIDS, may inapproprigown or glove before entering the patient's room, may over-isolate AIDS patients,
or may even refuse to treat AIDS patients altogether. Another repercussion of AIDS is a
family's discovery that a family member is a homosexual or an IV drug user. Further,
acting

ately

certain activities that contribute to the spread of AIDS, such as prostitution and
use, are illegal.
tion.

Knowledge of the

However, in a fear-driven

individuals with

AIDS may

individual's status

may be

society, failure to release information

subject

all

IV drug

followed by legal prosecu-

members of high-risk groups

about particular

to being ostracized,

denied benefits, and treated in a discriminatory fashion. Should such a societal response
justify invasion of an individual's privacy

and liberty?

Recognizing the importance of medical research, both the federal government and the
Massachusetts legislature provide mechanisms for protecting confidentiality by limiting
access to research records in certain cases.
a confidentiality certificate

Under

federal law, a researcher can apply for

when engaged in mental health research,

including research

on the use and effect of alcohol and psychoactive drugs, to prohibit access to information
by compulsory process. The Massachusetts statute similarly protects certain information
from release under subpoena. 12 Laws regarding the protection of confidentiality and ac11

may vary among states.
One major dilemma for researchers who learn that an individual has AIDS, ARC, or
HIV antibody positivity and may therefore be infectious is how to preserve the patient's

cess to research records

confidentiality while at the

AIDS.

same time protecting medical personnel from exposure

to

An example from Boston City Hospital will illustrate this point. When the HIV

antibody test was

first

developed,

it

was

available only for research

and blood bank use,

not for clinical purposes. At that time, the Centers for Disease Control and the Massachusetts state health

agencies

felt that, in

the absence of treatment for the

AIDS

antibody, the

information would be of little clinical value and would result only in negative conse-

quences for the patient. Since that time, the

CDC has become more interested in tracing

the course of the virus at earlier stages and has encouraged antibody testing in clinical
settings

where the information would

assist clinical

management.

Seroepidemiological studies of HIV with IV drug users, including a substantial number
of pregnant addicts, were conducted at a drug treatment clinic operated by Boston City
Hospital.

The researchers

in this instance

had information about the

clients

which they

could not disclose to other clinicians without proper consent. These other clinicians believed such information

would be invaluable

in the clients' treatment plans.
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was further complicated

for pregnant addicts,

a researcher and a clinician for them.
pediatric staffs at the hospital

because a particular physician could be both

How could the clinician advise the obstetric and

where the

clinician practiced,

and where the

deliver their babies, to take precautions against blood exposure

without disclosing the mother's

Should
In

all

AIDS

HIV

clients

from mother and

would

infant

antibody status, learned only through research?

high-risk mothers and infants be considered infectious?
research,

it

may be important to distinguish between

nymity. If the only concern

is

confidentiality

and ano-

an epidemiological analysis of prevalence, then anonymity

may be preferred. However, if there are good reasons — such as the ability to trace a
person with AIDS in order to provide therapeutically relevant data or to alert a victim that
a new therapy is available — then keeping patients' names in confidential files may be
preferred.

IRBs have emphasized

this distinction

cide whether anonymity or confidentiality

is

and have challenged researchers

to de-

preferable and for what reasons.

Conclusion

The ethical and

societal concerns about

AIDS

research which are raised by the relation-

ship between research findings, available clinical treatments, and public health policy
actions call for a national assessment of medical research priorities and intermediate goals
for

AIDS

research.

13

Assessments must then lead to directing research funds in accord-

ance with the national research agenda in the most cost-efficient manner. Such a public
policy could be cooperatively addressed by private researchers and institutions and public

agencies and officials. To

some extent, such forums have already been

established in

various states. For example, in Massachusetts the Governor's Task Force on

composed of researchers, public health
the

officials,

AIDS

is

and community representatives. All of

New England states have established similar investigational bodies.

State plans should

be consistent with broader, more comprehensive national agendas.

Many

ethical, legal,

and public policy considerations are involved

problems associated with
to recognize

practical and

AIDS research.

Professionals in

all

in addressing the

aspects of health care need

and understand the possible alternative approaches

to resolution of these

moral quandaries. IRBs can serve as locally based forums for the

initiation

of debate. Such boards have had ample experience in dealing with the substantive issues of
consent, confidentiality, the balancing of risks and benefits, and the proper selection of

populations for research. This experience
lines that assure

is

complemented by federally mandated guide-

proper procedures for the protection of human subjects in research. Since

the procedures are open to public scrutiny and since these boards have public representation,

IRBs are particularly appropriate forums

AIDS

for public participation in addressing

research.

Although the principles of biomedical
for persons, are not

unique to

ethics,

AIDS research,

tate a careful application of these principles.

such as beneficence, justice, and respect

the enormity and gravity of AIDS necessi-

The continuous balancing of the

welfare of individuals and the rights and welfare of the public
solving the complex ethical issues involved in

This article

is

AIDS

The

article is printed

rights

and

a crucial element in re-

research. *§>
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is

AIDS Research," which
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by permission of the Joint Commission on Accreditation of

Healthcare Organizations.
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"S

omeone once described AIDS like being

middle of a hurricane.

But when someone
frightening.
that

So

it is

we can bring

It's

is in

pretty lonely

that

in

a canoe

and its pretty

canoe with you

it's

with our coalition ofPWAs.

that

canoe

into

a safe harbor.
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in the

terrifying.

not nearly so

We even believe

